Asperulosidic Acid
(Synonyms: 车叶草苷酸) 目录号 : GC35412Asperulosidic Acid (ASPA) 车叶草苷酸是一种具有生物活性的环烯醚萜苷,从白花蛇舌草 (Hedyotis diffusa Willd) 的草药中提取的。 Asperulosidic Acid (ASPA) 具有抗肿瘤,抗氧化和抗炎作用。Asperulosidic Acid (ASPA) 通过抑制 NF-κB 和丝裂原活化蛋白激酶 (MAPK) 信号通路抑制炎性细胞因子(TNF-α,IL-6) 释放发挥抗炎作用。
Cas No.:25368-11-0
Sample solution is provided at 25 µL, 10mM.
Asperulosidic Acid (ASPA), a bioactive iridoid glycoside, is extracted from the herbs of Hedyotis diffusa Willd. Asperulosidic Acid (ASPA) has anti-tumor, anti-oxidant, and anti-inflammatory activities[1].ASPA is related to the inhibition of inflammatory cytokines (TNF-α, IL-6) and mediators via suppression of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways[2].
Asperulosidic Acid (ASPA) (40-160 μg/mL; pre- 1 hour) significantly down-regulates the mRNA levels of TNF-α and IL-6 in LPS-induced RAW 264.7 cells compared with the group treated with LPS alone [1].Asperulosidic Acid (ASPA) (40-160 μg/mL; pre- 1 hour) decreases IκB-α phosphorylation in a concentration-dependent manner, decreases Erk1/2 phosphorylation at all concentration levels, but there was no effect on p-p38 [1]. RT-PCR[2] Cell Line: RAW 264.7 cells
[1]. Xianyuan L , et al. Anti-renal fibrosis effect of asperulosidic acid via TGF-β1/smad2/smad3 and NF-κB signaling pathways in a rat model of unilateral ureteral obstruction. Phytomedicine. 2019 Feb;53:274-285. [2]. He J, et al. Asperuloside and Asperulosidic Acid Exert an Anti-Inflammatory Effect via Suppression of the NF-κB and MAPK Signaling Pathways in LPS-Induced RAW 264.7 Macrophages. Int J Mol Sci. 2018 Jul 12;19(7). pii: E2027.
Cas No. | 25368-11-0 | SDF | |
别名 | 车叶草苷酸 | ||
Canonical SMILES | OC[C@H]([C@@H](O)[C@H](O)[C@H]1O)O[C@@]1([H])O[C@H]2[C@@]3([H])[C@@]([C@@H](O)C=C3COC(C)=O)([H])C(C(O)=O)=CO2 | ||
分子式 | C18H24O12 | 分子量 | 432.38 |
溶解度 | DMSO : 100 mg/mL (231.28 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.3128 mL | 11.5639 mL | 23.1278 mL |
5 mM | 0.4626 mL | 2.3128 mL | 4.6256 mL |
10 mM | 0.2313 mL | 1.1564 mL | 2.3128 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet